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93.7% in age group 1 (0 ≤ 12 years) to 83.3% in age group 5 (older than 65 years). 
In general the lowest average reﬁ ll-based adherence rates were obtained with medicine 
items containing phenobarbitone and vitamin B1 (52.0% ± 37.8); phenobarbitone 
(63.5% ± 47.2); primidone metabolites (69.7% ± 47.2%); clonazepam (77.8% ± 
184.8) and carbamazepine (80.9% ± 151.1) CONCLUSIONS: Most of the anti-epi-
leptic drugs had unacceptable low reﬁ ll-adherence rates. Reﬁ ll-adherence rates of 
anti-epileptic drugs decreased with an increase in the age of patients.
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OBJECTIVES: To investigate the prevalence of unacceptable reﬁ ll-based adherence 
rates with antiparkinson medicine items. METHODS: A retrospective drug utilization 
study was performed on medicine claims data of a pharmacy beneﬁ t management 
company in South Africa during January 1, 2005 until December 31, 2008. Reﬁ ll-
based adherence rates were calculated for 8 768 antiparkinson medicine items that 
were prescribed more than once during a four-year period (January 1, 2005 to Decem-
ber 2008). The reﬁ ll-based adherence rate was calculated per trade name by using the 
following equation: Reﬁ ll-Adherence rate = (total number of days of antiparkinson 
medicine items supplied—days supplied at the last reﬁ ll)/(date last claimed—date ﬁ rst 
claimed). (RSA Rand(R)/$US = 6.8595 on 31 Dec. 2007). [RSA Rand (R)/$US = 
6.38112 (2005); 6.78812 (2006); 7.06926 (2007) and 8.27505 (2008)] RESULTS: A 
majority of antiparkinson medicine items (53.50%, n = 4,691) had unacceptably low 
reﬁ ll-adherence rates below 90%, that accounted for 41.62% (n = R16,398,512.00) 
of the total cost (N = R39,402,898.20) of all antiparkinson medicine items included 
in this study. Only 36.78% (n = 3225) of antiparkinson medicine items had acceptable 
reﬁ ll-adherence rates between 90% and 110%. Those with unacceptable high reﬁ ll-
adherence rates accounted for 9.72% (n = 852) of all antiparkinson medicine items 
and represented 6.5% (n = R2,574,597) of the total cost. No practical signiﬁ cant 
difference in the average reﬁ ll-adherence rates was found between male (93.99% ± 
186.99) and female (90.83% ± 175.21) patients. Biperidien, carbidopa/levodopa, and 
levodopa/benserazide containing products had on average unacceptable low reﬁ ll-
adherence rates (<90%). CONCLUSIONS: Although poor obedience to treatment 
schedules adds up to aggravation of Parkinson’s disease leading to death and ampliﬁ ed 
health care cost, it seems that the reﬁ ll-adherence rate of antiparkinson medicine items 
is not very favourable
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OBJECTIVES: The Scales for Outcomes in Patients with Parkinson’s disease Diary 
Card (SCOPA-DC) is a daily diary designed to measure motor impairment in Parkin-
son’s disease (PD) patients with ﬂ uctuating symptoms. Previous qualitative research 
evaluated the content validity of the SCOPA-DC in the US and expanded it to measure 
non-motor symptoms. The current research examined the psychometric properties of 
the revised SCOPA-DC. METHODS: A sample of adults age 30 and older with self-
reported doctor-conﬁ rmed PD were recruited, screened, and consented online from a 
Knowledge Networks panel. Eligible patients were mailed a study packet that con-
tained the revised SCOPA-DC as well as a training video. The revised SCOPA-DC 
included 7 non-motor items: fatigue, memory, anxiety, pain, difﬁ culty swallowing, 
frequent urination, and sweating. The diary was completed 7 times per day for 3 
consecutive days. Consistent with the original SCOPA-DC, 3-day scores were calcu-
lated for each item. Higher scores indicated greater symptom severity. RESULTS: A 
total of 101 PD patients completed and returned the revised SCOPA-DC. The sample 
was 50.5% male and had been diagnosed with PD for an average of 7.4 years. Fre-
quency distributions showed little missing data (approximately 1.0%), although items 
were generally right-skewed. Fatigue (29.4) and walking (28.7) had the highest mean 
scores; sweating (7.3) and difﬁ culty swallowing (9.7) had the lowest mean scores. 
Factor analysis supported a 3-factor solution: mobility, physical functioning, and 
psychological functioning. These factors demonstrated good internal consistency 
(alpha = 0.83–0.87) and correlations with health-related quality of life instruments 
were suggestive of construct validity. CONCLUSIONS: In this US sample of PD 
patients with varied disease severity, the revised SCOPA-DC exhibited good psycho-
metric properties, including evidence of reliability and validity. Furthermore, patients 
reported that the revised SCOPA-DC was clear and easy to complete. The revised 
SCOPA-DC holds promise for measuring a broad spectrum of ﬂ uctuating motor and 
non-motor PD symptoms.
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OBJECTIVES: There has been increasing interest novel HTA methods that will incor-
porate patient preferences in a more transparent and scientiﬁ cally valid way. The 
fundamental problem of the assessment of beneﬁ ts in HTA is the identiﬁ cation, 
ranking and valuation of multiple health care outcomes. We used two multi-criteria 
methods to rank and value ﬁ ve different treatments in stroke rehabilitation. Analytic 
Hierarchy Process (AHP) stems from operations research and is increasingly being 
used in health care to weigh patient-reported endpoints. Conjoint analysis (CA) is a 
stated preference method that often takes the discrete choice format. In CA, hypotheti-
cal scenarios are used to generate part-worth utilities for attributes. METHODS: To 
determine the clinical decision context and related criteria, a paper-and-pencil ques-
tionnaire was conducted among a sample of Dutch physiatrists united in a stroke 
interest group. From the lists of criteria (e.g. clinical beneﬁ t, impact of treatment) an 
expert panel deﬁ ned the AHP decision structure as well as the conjoint analysis survey 
format. Finally, the complete questionnaire including the AHP and CA survey was 
sent out to 184 patients with ankle-foot impairments. Eventually, 89 patients com-
pleted both surveys. RESULTS: On average, the prediction of preferred treatment on 
a group level is similar for both AHP and CA. However. on an inidividual level there 
seems to be more variation in treatment preference. Using AHP weights, a vast major-
ity preferred soft-tissue surgery where most patients preferred orthopedic shoes if CA 
weights were used. This may have been caused by labelling effects of the attributes. 
CONCLUSIONS: Both methods have there pros and cons in ranking and valuing 
patient-reported endpoints. Of the methods AHP is relatively easy to apply. In predic-
tion of overall outcome, both methods perform equally. However, for individual 
treatment preference we observed some differences. It may be concluded that the 
decision structure, framing and labelling of the treatment attributes are more impor-
tant than the speciﬁ c elicitation method used.
PND36
HEALTH STATUS COMPARISON BETWEEN STABLE PARKINSON’S 
DISEASE PATIENTS AND THOSE EXPERIENCING OFF-TIME
Buck PO1, White RE1, Castelli-Haley J1, Rendas-Baum R2, White MK2
1Teva Neuroscience, Kansas City, MO, USA; 2QualityMetric Incorporated, Lincoln, RI, USA
OBJECTIVES: End-of-dose wearing-off is commonly experienced by Parkinson’s 
disease (PD) patients who have used dopaminergic therapy for several years. Although 
investigations of wearing-off have traditionally focused on motor ﬂ uctuations, it is 
increasingly recognized that non-motor symptoms also vary between periods of “ON” 
(when PD symptoms are minimized due to medication) and “OFF” (when PD symp-
toms return). This study characterizes the self-reported health status of PD patients 
who experienced OFF-time as compared to those who were stable. METHODS: 
Recruited from an online panel maintained by Knowledge Networks, adults with 
self-reported doctor-conﬁ rmed PD were screened, consented, and completed a cross-
sectional survey. Frequency of OFF-time was measured using the Uniﬁ ed Parkinson’s 
Disease Rating Scale Part IV. Demographics, PD-speciﬁ c characteristics, the 9-item 
Wearing-off Questionnaire (WOQ-9), the Short Form-12v2 (SF-12), and the Parkin-
son’s Disease Questionnaire-8 (PDQ-8) were also assessed. RESULTS: Data were 
available for 165 PD patients (mean age = 66.6 years; 52.7% male; mean time from 
diagnosis = 7.1 years). Twenty-ﬁ ve (15%) of the patients reported experiencing no 
OFF-time on a typical day and were classiﬁ ed as stable; the remaining 85% reported 
experiencing OFF-time. There were few signiﬁ cant differences between the two groups 
in terms of demographics and PD history. Compared to those experiencing OFF-time, 
stable patients reported fewer motor and non-motor wearing-off symptoms based on 
the WOQ-9 (P < 0.05), as well as better health on the Physical and Mental Component 
Summary scores of the SF-12 (P < 0.05) and the Summary Index score of the PDQ-8 
(P < 0.01). CONCLUSIONS: PD patients who experienced at least some OFF-time 
on a typical day reported worse overall physical and mental well-being than stable 
patients. Furthermore, both motor and non-motor wearing-off symptoms differed 
between the two patient groups. Additional research to understand the consequences 
of OFF-time would be useful, especially as it pertains to non-motor symptoms.
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OBJECTIVES: To compare patients’ and physicians’ global perceptions of Parkinson’s 
disease (PD) in two treatment groups: levodopa/carbidopa/entacapone (LCE) vs. 
levodopa/carbidopa (LC). METHODS: Multicentre, double-blind, randomised phase 
IV study. Ninety-ﬁ ve PD patients with early wearing-off (WO) and deterioration of 
activities of daily living (ADLs) were randomised to receive LCE (n = 46) or LC (n = 
49) with a 3-month follow-up. Patient and physician global perception of PD was 
assessed at the end of the study. The PDQ-39 quality of life (QoL) questionnaire, and 
the longitudinal course of PD using the different parts of UPDRS (part I, part II, part 
III, and IV) were evaluated along the study. Differences between health improvement 
by patient and physician were analyzed by the Mann Whitney U-test. The mean dif-
ferences from baseline to ﬁ nal visit in PDQ-39 and in UPDRS (part I, II, IIII IV) score 
were analyzed by an ANCOVA model. RESULTS: Mean (SD) age was 66.4 ± 8.6 
years and 50.0% were women. Half percent of patients showed stage II according to 
the Hoehn and Yahr classiﬁ cation. Patient global perception showed a signiﬁ cant 
better score in the LCE than in LC group (−0.9 ± 1.0 LCE and −0.4 ± 1.17 LC, p = 
0. 0291). Similar results were obtained by the physician (−0.3 ± 0.8 vs. −0.4, p = 0. 
0017). The adjusted mean differences in the PDQ-39 showed a trend for a higher 
improvement in QoL in the LCE group (6.3 ± 20.4 vs. 0.81 ± 15.6), although did not 
reach statistical signiﬁ cance. The UPDRS evaluation showed a signiﬁ cant higher 
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response in part II and III (p = 0.0078 and p = 0.0072, respectively). a trend to better 
results for the LCE group was observed in part I and IV. CONCLUSIONS: Levodopa/
carbidopa/entacapone shows a signiﬁ cant better patient and physician global percep-
tion in the LCE treatment group vs. LC group in PD patients with early WO and 
ADLs deterioration.
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OBJECTIVES: Since its development in the 80’s, variations of the Alzheimer’s Disease 
Assessment Scale-Cognitive subscale (ADAS-Cog), a Clinician-Reported Outcome 
(ClinRO) measure, have been used to monitor disease progression and treatment 
efﬁ cacy in Alzheimer’s disease. The objective of this study was to identify all versions 
used as a basis for translation in Mapi Institute projects and to take stock of existing 
translations. METHODS: The review was based on all ADAS-Cog translation projects 
performed by Mapi Institute. RESULTS: Sixteen projects were identiﬁ ed representing 
a total of 70 languages and 219 translations. Translations were based on 11 source 
versions which differed in terms of content (number of items, order of items and 
instructions), and format. The number of items ranged from 11 to 15. Four studies 
used 13 items, but only in two cases the same items were used although in a different 
order. Four studies used 12 items: only two studies used the same items (with a dif-
ferent list of words for the Word Recognition Task), but again in a different order. 
Format and instructions differed in all cases. In most projects the source version 
provided by the sponsor was a single document mixing instructions with the rater and 
response forms. Only in 3 cases the original consisted in a separate instruction manual 
and response forms. With regard to available translations, more than one translation 
was identiﬁ ed in 56 of the 70 available languages and in one language (Swedish) as 
many as 7 translations. CONCLUSIONS: The abundance of different versions of the 
same questionnaire both in its original US English form as in translations makes 
comparisons between studies or pooling of data difﬁ cult for both researchers and 
users. In the light of FDA’s recent PRO guidance it would be beneﬁ cial to demand 
the same scientiﬁ c rigor when using ClinROs in international studies.
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OBJECTIVES: Quality of life (QoL) is an important measure that is often overlooked 
in the assessment of multiple sclerosis (MS). The MS International QoL (MusiQoL) 
questionnaire is a validated, MS-speciﬁ c instrument. This study aimed to assess the 
responsiveness of the MusiQoL questionnaire to changes in Expanded Disability 
Status Scale (EDSS) scores in patients with MS. METHODS: In this ongoing, 
24-month, multicentre, observational study, MusiQoL and EDSS scores were recorded 
at baseline (BL) and at 6-month intervals. The primary endpoint is change in MusiQoL 
index score from BL to month 24 (including effect size). Secondary endpoints include 
change in MusiQoL index score from BL to month 12 and change in MusiQoL scale 
scores. RESULTS: Of 600 patients enrolled, 474 had evaluable BL and month-12 
EDSS and MusiQoL index data. At BL, mean (SD) EDSS score was 2.9 (1.9); mean 
(SD) MusiQoL index score was 68.5 (14.4); and mean (SD) MusiQoL scale scores 
ranged from 59.9 (24.8) to 85.4 (18.5). At month 12, 68 patients (14.3%) had a worse 
EDSS score than that recorded at BL. Mean (SD) change in MusiQoL index score was 
0.48 (10.99) overall, and −1.00 (9.88) in “worsened” patients; effect sizes were 0.03 
and −0.08, respectively. Changes from BL to month 12 in MusiQoL scale scores were 
mostly small. However, there were larger (mean [SD]) decreases in some subscales at 
month 12 for “worsened” patients: “Activities-of-daily-living” (−4.20 [18.07]); “Rela-
tionship-with-family” (−5.14 [23.43]); ‘Sentimental-and-sexual-life’ (−4.11 [17.56]); 
and ‘Relationship-with-health care-system’ (−3.56 [14.11]). Effect sizes were −0.17, 
−0.25, −0.14 and −0.21 respectively. Conversely, the mean (SD) change in ‘Symptoms’ 
score was 5.36 (17.27) at month 12 for ‘worsened’ patients (effect size: 0.24). CON-
CLUSIONS: As expected, most MusiQoL scores decreased over 12 months in patients 
with worsening EDSS scores, indicating poorer QoL and conﬁ rming the utility of the 
MS-speciﬁ c MusiQoL in rating QoL.
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OBJECTIVES: Huntington’s disease (HD) is a rare neurodegenerative disease leading 
to sustained disability for patients and poor quality of life (QoL) for patients as well 
as caregivers. This study investigated the impact of HD on caregivers’ QoL and its 
drivers. METHODS: The European HD burden study (Euro-HDB) is an ongoing 
cross-sectional survey among HR patients and their caregivers in six countries (France, 
Italy, Germany, UK, Sweden and Spain). The Huntington’s disease Quality of Life 
Battery for Carers (HDQoL-C) short-version, a previously validated questionnaire by 
Aubeeluck A. and Buchanan H., was administered. Pearson correlations with generic 
HR-QOL (SF36, EQ5D) and the speciﬁ c HR-QOL in HD for patients (HQOLI) were 
evaluated. The determinants of caregiver QOL among drivers among patients’ clinical 
characteristics (voluntary movement disorders, chorea, depression/anxiety, psychotic 
disorder, cognition, temper) were studied by regression analysis adjusting on age, sex 
and occupational categories. The relationship between QOL of patients and caregivers 
were also explored. RESULTS: To date, 201 caregivers in France and 124 in Italy 
have been enrolled. For France (respectively Italy) 6% (12%) were completely unsatis-
ﬁ ed by their overall QOL and 7% (5%) were totally satisﬁ ed. HDQoL-C scores were 
poorly correlated with generic caregiver HR-QOL: correlation equaled 0.31 for EQ5D 
utility and varied between 0.04 and 0.45 for the eight domains of SF36. Correlation 
was quite high (0.59; P < 0.01) between HDQoL-C and HQOLI. Drivers of caregiver’s 
QoL were voluntary movement disorders (p = 0.049), depression/anxiety (p = 0.02), 
psychotic disorder (p = 0.01) and cognition (p = 0.01). Temper and chorea were not 
drivers of caregivers’ QOL independently of other clinical characteristics. CONCLU-
SIONS: Caregivers QOL worsens as the patient clinical characteristics deteriorate 
especially voluntary movement disorders, depression/anxiety, psychotic disorders and 
cognition disorders. Patients and caregiver QoL was indirectly correlated via patient 
clinical scores. The potential impact on caregiver QOL should be considered in evalu-
ations of innovative HD treatments.
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OBJECTIVES: This study assesses, for an estimated EU pain population of 50 million 
patients, the impact of pain severity and frequency on three dimensions of health 
related quality of life (HRQoL): the SF-12 MCS and PCS scores and (ii) the SF-6D 
absolute utility scores. METHODS: The study is based on data from the internet based 
2008 National Health and Wellness Survey undertaken in the UK, France, Spain, 
Germany and Italy. This study identiﬁ ed 11,000 respondents (1 in 5 of the estimated 
big 5 EU countries) who had experienced pain in the last month. The assessment of 
the quantitative impact of pain status on HRQoL is estimated via three single equation 
generalized linear (ordinary least squares) models which estimate the impact of pain 
on PCS, MCS and utility scores. The model includes a range of variables which have 
been shown in previous population studies to impact HRQoL. These include: socio-
demographic factors, health risk behaviors, comorbidity status, medication utilization, 
duration of medication utilization and satisfaction with care. The experience of pain 
is captured by a combination of severity and frequency categorical variables. 
RESULTS: Pain has a substantial impact on all three of the dimensions of HRQoL 
considered here. Compared to the reference category (mild pain experienced weekly 
or less) the presence of severe, daily pain has a substantial impact on SF-12 PCS scores 
(−13.85 points); SF-12 MCS scores (−4.72); and SF-6D utilities (−0.147). There is a 
marked gradient on scores by severity and frequency of pain experience. The impact 
of pain on HRQoL is more signiﬁ cant than the impact of socio-demographic charac-
teristics, health risk factors, comorbidities and the experience of pain medication. 
CONCLUSIONS: The presence of moderate and severe pain imposes a signiﬁ cant 
burden on persons reporting pain in the big 5 EU countries; the burden increases the 
greater the frequency and severity.
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OBJECTIVES: The aim of the study was to survey some objective and subjective 
indicators determining the quality of life of people with Down’s syndrome (DS), born 
between 1975 and 2005, looked after in their families in the Southern-Transdanubian 
region of Hungary. The relationship between the parental level of education and the 
above factors was explored. METHODS: On the basis of the VRONY database 
(National Registry of Congenital Anomalies) health visitors contacted families looking 
after DS people (N = 107), and conducted anonymous, questionnaire surveys in 
2008–2009. Reading was examined from school-age (N = 79), drawing and writing 
was examined depending on age. RESULTS: The abilities under examination moved 
